Clinical Research

At Arthritis and Rheumatic Diseases Specialties, we have a passion to provide the best care to our patients and improve their quality of life. We focus on the efficient diagnosis to start their way back to normal, satisfactory quality of life.

As leaders in our fields, we continually contribute to the development of new treatments and protocols by participating in clinical research. Clinical research is highly satisfactory for us, because it allows us to achieve two important goals: to help patients who need treatment options in the short term, and to contribute to the approval of better treatment protocols in the long term.

Right now, the following clinical studies are open. Please contact us by email at clinicalresearch@rheum-care.com or call us at 305-652-6676 to obtain more information on how to participate in these studies.

These links will take you to the description of the clinical trials being conducted currently in the office under the clinical trials.gov website. You can read about the specific trial and see the Inclusion/Exclusion criteria to see if you qualify to participate.

Rheumatoid Arthritis:

  • Protocol RA-012018 RA Investigator Initiated Study: Measurement of the Structural Efficacy in Active Rheumatoid Arthritis (RA) Patients Treated with Sarilumab in Combination with Methotrexate (MTX) and Naïve to Biologics as Measured by Low-field MRI using a Modified OMERACT-RAMRIS score (recruiting)
  • SetPoint SPM-008: A Randomized Controlled Study of the Safety and Efficacy of Neurostimulation Using a Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis (recruiting)
  • A Phase 3, Randomized, Double-blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologics DMARDs (bDMARDs) (ongoing)
  • A Phase 3, Randomized, Double-blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderaltey to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have as Inadequate Response to MTX (MTX-IR) (ongoing)
  • A Phase 3b/4 Randomized Double-blind Placebo Controlled Study of Methotrexate (MTX) Withdrawal in Subjects with Rheumatoid Arthritis (RA) Treated with Tofacitinib 11 mg Modified Release (MR) Formulation (ongoing)
  • A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment (ongoing)
  • A Randomized, Double-blind Phase 3 Study to Assess the Efficacy and Safety of ABP710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis (ongoing)
  • A Phase 3 Randomized, Double-blind Study Assessing the Efficacy and Safety of PF-06410293 and Adalimumab in Combination with Methotrexate in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate (ongoing)

Systemic Lupus Erythematosus:

Psoriatic Arthritis (PsA):

Osteoarthritis:

If you or anyone you know has been diagnosed with an autoimmune disorder including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Ankylosing Spondylitis and Gout and may be interested in participating in a clinical research trial, please call the Research Department at 305-652-6676 to discuss the inclusion and exclusion criteria for participation in a clinical trial

Ankylosing Spondylitis AS

Copyright © 2018 Arthritis & Rheumatic Disease Specialties | Nondiscrimination | Privacy Practices | Limited English Assistance Services